Is NCT06941441 recruiting in Seattle, WA?

Yes, NCT06941441 is currently recruiting participants at its Seattle, WA location. This pulmonary arterial hypertension (pah) clinical trial is actively enrolling qualified participants.

Is participation in this Seattle clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Pulmonary Arterial Hypertension (PAH) Clinical Trial in Seattle, WA

Q: How do I join the pulmonary arterial hypertension (pah) clinical trial in Seattle?

To join this clinical trial in Seattle, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Pulmonary Arterial Hypertension (PAH) Study in Seattle

Ten patients with PAH who are stable and eligible to initiate sotatercept therapy will participate in a 26 week study that consists of a 24-week intervention period where patients will receive complimentary sotatercept as prescribed, plus a tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring.

Sponsor: University of Washington

Who Can Participate

Inclusion Criteria

Age ≥ 18 years

Documented diagnostic right heart catheterization (RHC) at any time prior to screening confirming the diagnosis of WHO PAH Group 1 in any of the following subtypes: Idiopathic PAH, Heritable PAH, Drug/toxin-induced PAH, PAH associated with CTD, PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following repair

Symptomatic PH classified as WHO FC II or III

Baseline RHC performed during the Screening Period documenting a minimum PVR of ≥ 5 WU and a pulmonary capillary wedge (PCWP) or left ventricular end-diastolic pressure of ≤ 15 mmHg

Receiving stable background therapy for PAH for \>90 days and will continue receiving throughout trial. Background treatments may consist of monotherapy, double therapy, or triple therapy with currently available medications for PAH.

Initiation of Sotatercept is clinically indicated

Willing and able to participate in a remotely-monitored home exercise program for 24 weeks

Ability to adhere to study visit schedule and understand and comply with all protocol requirements

Ability to understand and provide written informed consent

Exclusion Criteria

Diagnosis of PH WHO Groups 2, 3, 4, or 5

Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis-associated PAH and pulmonary veno-occlusive disease

Hemoglobin at screening above gender-specific ULN

Baseline platelet count \< 50,000/mm3 (\< 50.0 × 109/L) at screening

Uncontrolled systemic hypertension as evidenced by sitting systolic BP \> 160 mmHg or sitting diastolic BP \> 100 mmHg during screening visit after a period of rest; Baseline systolic BP \< 90 mmHg at screening

Pregnant or breastfeeding females

Clinical laboratory liver and kidney function tests outside of normal range

Currently enrolled in or have completed any other investigational product study within 30 days for small-molecule drugs or within 5 half-lives for biologics prior to the date of signed informed consent

Prior exposure to sotatercept (ACE-011) or luspatercept (ACE-536) or known allergic reaction to either one

History of full pneumonectomy

Initiation of a structured exercise program within 90 days prior or planned initiation during the study

Known history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication), defined as mild to severe hepatic impairment (Child-Pugh Class A-C).

Cardiac related history: History of restrictive, constrictive, or congestive cardiomyopathy; History of atrial septostomy within 180 days prior to the screening visit; ECG with Fridericia's corrected QT interval (QTcF) \> 500 ms during the Screening Period; Personal or family history of long QT syndrome (LQTS) or sudden cardiac death; Left ventricular ejection fraction (LVEF) \< 45% on historical ECHO within 12 months prior to the screening visit; Any symptomatic coronary disease events (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) within 6 months prior to the screening visit. Note: Anginal pain can be ignored as an exclusion criterion if coronary angiography shows no obstructions

Cerebrovascular accident within 3 months prior to the screening visit

Acutely decompensated heart failure within 14 days prior to the screening visit, as per investigator assessment

Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease

Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin) within 30 days prior to the screening visit

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Seattle?

Yes, this clinical trial (NCT06941441) has an active research site in Seattle, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pulmonary Arterial Hypertension (PAH) Treatment Options in Seattle, WA

If you're searching for pulmonary arterial hypertension (pah) treatment options in Seattle, WA, this clinical trial (NCT06941441) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Seattle research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pulmonary arterial hypertension (pah) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pulmonary arterial hypertension (pah) clinical trials near you to find additional studies recruiting in your area.

Pulmonary Arterial Hypertension (PAH) Clinical Trial in Seattle, WA

Expert Care in Seattle

IRB Approved

No-Cost Care

Apply for This Seattle Location

Why Participate?

Simple Process